New therapeutic option for irritable bowel syndrome: Serum-derived bovine immunoglobulin

Table 1 Presentation of irritable bowel syndrome patients with diarrhea

Patient No./age (yr)/gender	Primary symptoms	Comorbidity	Other GI therapy	SBI therapy/duration	Outcome
IBS-D 1/24/M	Diarrhea, frequency	Chronic urethritis	Low FODMAP diet,	Ongoing	Complete resolution of symptoms
	urgency,	ulcerative proctitis	mesalamine	32 wk
	ABD pain
IBS-D 2/36/F	Diarrhea	Hypothyroidism	None	Ongoing	Marked improvement in urgency and diarrhea
	urgency	anxiety,		18 wk
	incontinence	depression
IBS-D 3/63/M	Diarrhea	Eosinophilic esophagitis,	Pantoprazole	Ongoing	Complete resolution of symptoms
	Flatulence,	RIH,		27 wk
	ABD cramps,	BPH
	urgency
IBS-D 4/86/M	Loose stools,	COPD,	Domperidone	Ongoing	Marked improvement of urgency and diarrhea
	urgency,	lung cancer		12 wk
	cramping
IBS-D 5/36/F	Diarrhea,	Ulcerative colitis	Low FODMAP diet,	Ongoing	No ABD pain, Loose stools/diarrhea improved
	severe ABD pain		mesalamine	12 wk
IBS-D 6/87/F	Diarrhea,	Osteoporosis,	Perphenazine/amitriptyline,	Ongoing	Dramatic reduction in symptoms
	ABD pain,	GERD,	omeprazole	17 wk
	distention,	anxiety
	urgency
IBS-D 7/66/M	Diarrhea,	Hypertension,	Tramadol	Ongoing	Marked reduction in pain and urgency,
	urgency,	benign prostatic hyperplasia		16 wk	Formed bowel movements
	incontinenc,
	ABD pain

ABD: Abdominal; IBS-D: Irritable bowel syndrome with diarrhea; SBI: Serum-derived bovine immunoglobulin; GI: Gastrointestinal; GERD: Gastroesophageal reflux disease.

Table 2 Presentation of irritable bowel syndrome patients with constipation

Patient No./age (yr)/gender	Primary symptoms	Comorbidity	Other GI therapy	SBI therapy/duration	Outcome
IBS-C 1/22/F	Constipation, bloating,	None	Low FODMAP diet,	Discontinued after 11 wk	Ineffective
	distension		linaclotide,
			lubiprostone
IBS-C 2/55/F	Bloating,	Non-erosive reflux disease	lubiprostone	Ongoing	Reduced bloating and distension,
	distension,			14 wk	obstipation unchanged
	nausea,
	obstipation

IBS-C: Irritable bowel syndrome with constipation; SBI: Serum-derived bovine immunoglobulin; GI: Gastrointestinal.

Table 3 Presentation of irritable bowel syndrome patients with mixed with alternating constipation and diarrhea

Patient No./age (yr)/gender	Primary Symptoms	Comorbidity	Other GI Therapy	SBI Therapy/Duration	Outcome
IBS-M 1/33/F	Alternating diarrhea and constipation,	Morbid obesity	Low FODMAP diet	Ongoing	Overall improvement,
	bloating, distension,			15 wk	mild obstipation,
	ABD pain				reduced bloating
IBS-M	Alternating diarrhea and constipatio, bloating, distension	Osteoporosis	Low FODMAP diet	Ongoing	No bloating or distension, improved bowel movements
2/66/F				14 wk

IBS-M: Irritable bowel syndrome with mixed with alternating constipation and diarrhea; SBI: Serum-derived bovine immunoglobulin; GI: Gastrointestinal.

Table 4 Presentation of patients with irritable bowel syndrome -bloating

Patient No./age (yr)/gender	Primary symptoms	Comorbidity	Other GI therapy	SBI therapy/duration	Outcome
IBS-U 1/50/M	Gas,	GERD,	polycarbophil,	Ongoing	Resolution of symptoms
	Bloating,	osteoarthritis	saccharomyces boulardii lyo,	35 wk
	ABD Pain		polyethylene glycol 3350, prn
IBS-U	Severe ABD pain,	Hypertension,	Antidiarrheals	Discontinued after 6 wk	Unimproved
2/82/F	bloating,	atherosclerotic cardiovascular disease
	distension
IBS-U	Bloating,	Osteoporosis	denosumab,	Completed after 8 wk	Resolution of symptoms
3/62/F	distension,		rifaximin,
	ABD pain,		Low FODMAP diet
	flatulence

IBS-Bloating: Irritable bowel syndrome with bloating; SBI: Serum-derived bovine immunoglobulin; GI: Gastrointestinal; GERD: Gastroesophageal reflux disease.